Below are the most recent publications written about "Thrombocytopenia" by people in Profiles.
-
Treverton J, Arnold DM, Ivanov DG, Ivetic N, Zhang Y, Ali HA, Clare R, Kaltashov IA, Kelton JG, Nazy I. Monoclonal Antibodies in the Pathogenesis of Heparin-Induced Thrombocytopenia. N Engl J Med. 2025 Sep 04; 393(9):879-886.
-
Rejeski K, Sanz J, Fei T, Nair MS, Hashmi H, Avigdor A, Beyar-Katz O, B?cklein VL, Curran KJ, Einarsdottir S, Esensten JH, Glaubach N, Golan-Accav N, Gomez-Llobell M, Halamis I, Itzhaki O, Locke FL, Mailankody S, Marcus R, Maus MV, Palomba ML, Park JH, Pasquini M, Raj S, Rajeeve S, Salles G, Scordo M, Shah GL, Shimoni A, Subklewe M, Tix T, Usmani SZ, Valid O, Valtis YK, Zuckerman T, Shah NN, Perales MA, Shouval R. T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy. Blood. 2025 Aug 14; 146(7):834-846.
-
Sukumaran M, Cantrell DR, D'Agostino C, Jahromi BS, Ansari SA, Potts MB. Bivalirudin as a substitute for heparin in neurointervention for patients with heparin-induced thrombocytopenia. J Stroke Cerebrovasc Dis. 2024 Jun; 33(6):107310.
-
Yang Y, Du Y, Ivanov D, Niu C, Clare R, Smith JW, Nazy I, Kaltashov IA. Molecular architecture and platelet-activating properties of small immune complexes assembled on heparin and platelet factor 4. Commun Biol. 2024 03 11; 7(1):308.
-
Srichawla BS, Presti K, Kipkorir V, Berrios Morales I. Chemotherapy-associated hemorrhagic posterior reversible encephalopathy syndrome (PRES) with considerations for circle of Willis variants on cerebral blood flow and autoregulation: A case report. Medicine (Baltimore). 2024 Feb 23; 103(8):e37250.
-
Habibi S, Hsieh TC, Khanna S. Perioperative Plasma Exchange and Intravenous Immunoglobulin Use for Refractory Heparin-Induced Thrombocytopenia in a Liver Transplant Recipient. Am J Case Rep. 2023 Dec 30; 24:e941865.
-
Ivanov DG, Ivetic N, Du Y, Nguyen SN, Le SH, Favre D, Nazy I, Kaltashov IA. Reverse Engineering of a Pathogenic Antibody Reveals the Molecular Mechanism of Vaccine-Induced Immune Thrombotic Thrombocytopenia. J Am Chem Soc. 2023 11 22; 145(46):25203-25213.
-
Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Bumma N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Dinner S, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023 Oct; 10(10):e825-e837.
-
Ippolito MM, Kabuya JB, Hauser M, Kamavu LK, Banda PM, Yanek LR, Malik R, Mulenga M, Bailey JA, Chongwe G, Louis TA, Shapiro TA, Moss WJ. Whole Blood Transfusion for Severe Malarial Anemia in a High Plasmodium falciparum Transmission Setting. Clin Infect Dis. 2022 11 30; 75(11):1893-1902.
-
Revel-Vilk S, Naamad M, Frydman D, Freund MR, Dinur T, Istaiti M, Becker-Cohen M, Falk R, Broide E, Michelson AD, Frelinger AL, Zimran A. Platelet Activation and Reactivity in a Large Cohort of Patients with Gaucher Disease. Thromb Haemost. 2022 06; 122(6):951-960.